Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance
Qingmin Zeng,
Chang-Hai Liu,
Javier Ampuero,
Dongbo Wu,
Wei Jiang,
Lingyun Zhou,
Hong Li,
Lang Bai,
Manuel Romero-Gómez,
Hong Tang
Affiliations
Qingmin Zeng
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China
Chang-Hai Liu
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China
Javier Ampuero
Digestive Diseases Unit, Virgen del Rocío University Hospital. SeLiver group at Institute of Biomedicine of Seville (IBIS: HUVRocío/CSIC/US). University of Seville, Seville, Spain
Dongbo Wu
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China
Wei Jiang
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China
Lingyun Zhou
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China
Hong Li
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China
Lang Bai
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China
Manuel Romero-Gómez
Digestive Diseases Unit, Virgen del Rocío University Hospital. SeLiver group at Institute of Biomedicine of Seville (IBIS: HUVRocío/CSIC/US). University of Seville, Seville, Spain
Hong Tang
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China
Nonalcoholic fatty liver disease (NAFLD), which affects approximately 25% of the global population, is an urgent health issue leading to various metabolic comorbidities. Circular RNAs (circRNAs), covalently closed RNA molecules, are characterized by ubiquity, diversity, stability, and conservatism. Indeed, they participate in various biological processes via distinct mechanisms that could modify the natural history of NAFLD. In this review, we briefly introduce the biogenesis, characteristics, and biological functions of circRNAs. Furthermore, we summarize circRNAs expression profiles in NAFLD by intersecting seven sequencing data sets and describe the cellular roles of circRNAs and their potential advantages as biomarkers of NAFLD. In addition, we emphatically discuss the exosomal non-coding RNA sorting mechanisms and possible functions in recipient cells. Finally, we extensively discuss the potential application of targeting disease-related circRNAs and competing endogenous RNA networks through gain-of-function and loss-of-function approaches in targeted therapy of NAFLD.